Best EndoPredict® Breast Cancer Test in Dubai: At-Home Genomic Screening
Deciding on chemotherapy is one of the most significant moments in breast cancer recovery. In Dubai, patients are increasingly turning to EndoPredict®—a second-generation genomic test—to determine if they can safely avoid chemotherapy. With our at-home sample collection service, you can access world-class precision medicine without visiting a hospital
WHAT is the EndoPredict® Test?
EndoPredict® is a second-generation multigene test used specifically for patients with ER-positive, HER2-negative early-stage breast cancer.Unlike standard pathology, it analyzes the activity of 12 specific genes within your tumor to provide an EPclin® Risk Score. This score accurately predicts the likelihood of the cancer spreading (distant recurrence) over the next 10 to 15 years. It is a vital tool for personalized cancer care in the UAE, helping to distinguish between “True Low Risk” and “High Risk” patients.
WHY should you choose EndoPredict® over other tests?
Understanding Breast Cancer : Symptoms
→ A New Lump: Usually feels like a hard, painless mass with irregular edges; sometimes tender or soft.
→ Swelling: Unexplained swelling of all or part of the breast, even if no distinct lump is felt.
→ Skin Dimpling: Skin may look like an orange peel (peau d’orange) or develop small indentations.
→ Size or Shape Changes: Noticeable change in contour, symmetry, or “hang” of one breast compared to the other.
→ Persistent Heat or Redness: Breast may feel warm or appear red, purple, or inflamed.
→ Nipple Inversion: A nipple that suddenly pulls inward or changes orientation.
→ Nipple Discharge or Crusting: Fluid leaking from the nipple that is not breast milk, particularly if bloody, or redness, flaking, or thickening of the nipple/areola.
→ Lumps or Tenderness in the Underarm: Dull ache, sharp pain, or lumps under the arm or around the collarbone that persist.
The Role of Genomic Testing (EndoPredict®)
Once a diagnosis is made, the focus shifts to treatment planning. For those with ER-positive, HER2-negative breast cancer, the EndoPredict® test serves as a critical secondary step.Unlike a biopsy that simply identifies the presence of cancer, this genomic test looks at the molecular level (the activity of 12 specific genes) to determine the “aggressiveness” of the tumor.
- Low Risk: The cancer has a low probability of returning, potentially allowing the patient to safely bypass chemotherapy and its side effects.
- High Risk: The test indicates a higher likelihood of recurrence, suggesting that chemotherapy is a necessary addition to the treatment plan.
Frequently Asked Questions
EndoPredict is a second-generation genomic test used to predict the likelihood of breast cancer recurrence and determine if a patient will benefit from chemotherapy.
It is designed for women with early-stage, ER-positive, HER2-negative invasive breast cancer, including those with up to three positive lymph nodes.
Results are typically available within 7 to 10 working days, as the testing can be performed locally in specialized UAE labs.
No, it uses the “fixed” tissue sample (FFPE) already taken during your initial biopsy or tumor removal surgery.
An EPclin Risk Score below 3.3 is considered low risk, meaning there is less than a 10% chance of recurrence over 10 years without chemotherapy.
Unlike first-generation tests, EndoPredict provides information on both early (0–10 years) and late (up to 15 years) recurrence risk, and it is validated for both node-negative and node-positive patients.
It is “second-generation” because it combines molecular gene expression data with clinical factors like tumor size and nodal status to create a more accurate “EPclin” score.
Yes. If the test returns a “Low Risk” result, clinical guidelines suggest that the absolute benefit of chemotherapy is minimal, allowing many patients to safely choose hormone therapy alone.
Yes, it is specifically designed to help doctors decide if a patient needs extended endocrine (hormone) therapy beyond the standard five-year mark.
Yes, clinical studies have validated EndoPredict’s accuracy for both premenopausal and postmenopausal women.
The test analyzes 12 genes in total: 8 cancer-related genes, 3 reference genes for normalization, and 1 control gene.
The EPclin score is a calculated value that integrates the 12-gene molecular score with the patient’s tumor size and lymph node status
It is highly accurate and backed by Level 1A clinical evidence, included in major international guidelines like NCCN, ASCO, and St. Gallen.
A high-risk score ($>3.3$) indicates a higher probability of recurrence. In this case, your oncologist will likely recommend adding chemotherapy to your treatment plan to lower that risk.